Ciraparantag for haemorrhage in patients receiving new oral anticoagulants
NIHR HSRIC
Record ID 32016001031
English
Authors' recommendations:
Ciraparantag is a new drug to treat bleeding in people taking new oral anticoagulants (NOACs). Anticoagulants are medicines which are given to people to thin the blood and prevent blood clots. Anticoagulation can become a problem when patients experience major bleeding, have a traumatic injury or require emergency surgery. There are currently no licensed treatments that can quickly reverse the effects of NOACs in an emergency.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/ciraparantag-for-haemorrhage-in-patients-receiving-new-oral-anticoagulants/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Anticoagulants
- Hemorrhage
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.